Want to see GB:CRW full AI Analyst Report?
CRW Stock Chart & Stats
1300.00 p
2.00 p(0.15%)
At close: 4:00 PM EDT
1300.00 p
2.00 p(0.15%)
Day’s Range― - ―
52-Week Range988.00 p - 2,450.00 p
Previous CloseN/A
Volume192.74K
Average Volume (3M)270.39K
Market Cap
£372.65M
Enterprise Value678.49M
Total Cash (Recent Filing)£55.10M
Total Debt (Recent Filing)£46.77M
Price to Earnings (P/E)26.7
Beta0.91
Next Earnings
Mar 08, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.01%
Share Statistics
EPS (TTM)0.56
Shares Outstanding34,237,150
10 Day Avg. Volume106,858
30 Day Avg. Volume270,390
Financial Highlights & Ratios
PEG Ratio8.62
Price to Book (P/B)1.95
Price to Sales (P/S)3.02
P/FCF Ratio14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,600.00Price Target Upside23.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.8
Revenue Forecast (FY)£186.21M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And RetentionA substantial recurring revenue base with approximately 100% net revenue retention and customer retention above 90% supports visibility and reduces dependence on new bookings. These characteristics also create opportunities to expand module adoption within established hospital relationships over the next several quarters.
Cash Generation And LiquidityStrong cash conversion and net cash after bank debt provide financial flexibility to fund product investment, absorb operating volatility, and support customers through disruption. Undrawn credit capacity further strengthens Craneware’s ability to pursue its strategy without relying solely on near-term operating cash flow.
Product Investment And InnovationContinued investment in data integration, AI-enabled applications, and pharmacy capabilities can deepen the platform’s relevance to hospital finance and clinical workflows. Sustaining research and development at roughly 25%–30% of revenue supports product differentiation and future expansion potential.
Bears Say
340B Exposure And Revenue ResetThe fiscal 2027 revenue reset indicates that growth has been deferred while Craneware faces uncertainty in the 340B market. Restrictions on 340B pricing and changing business models may continue to pressure transactional revenue, making near-term growth less predictable despite stable ARR.
Cybersecurity Exposure And CostsThe incident creates an ongoing business risk because data exposure may require continuing customer support, remediation, and compliance work. Management has not yet quantified the financial impact, and the possibility that costs extend across future periods reduces confidence in near-term earnings visibility.
Margin Pressure And VolatilityLower gross margin and the expectation that margins will remain below 30% through fiscal 2027 indicate reduced earnings conversion during the transition period. The mix shift toward technology-enabled services and ongoing cost actions may constrain profitability until the planned fiscal 2028 recovery.
Craneware News
CRW FAQ
What was Craneware Plc’s price range in the past 12 months?
Craneware Plc lowest share price was 988.00 p and its highest was 2450.00 p in the past 12 months.
What is Craneware Plc’s market cap?
Craneware Plc’s market cap is £372.65M.
When is Craneware Plc’s upcoming earnings report date?
Craneware Plc’s upcoming earnings report date is Mar 08, 2027 which is in 136 days.
How were Craneware Plc’s earnings last quarter?
Craneware Plc released its earnings results on Sep 21, 2026. The company reported 0.212 p earnings per share for the quarter.
Is Craneware Plc overvalued?
According to Wall Street analysts Craneware Plc’s price is currently Undervalued.
Does Craneware Plc pay dividends?
Craneware Plc pays a Semiannually dividend of 17 p which represents an annual dividend yield of 3.01%. See more information on Craneware Plc dividends here
What is Craneware Plc’s EPS estimate?
Craneware Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Craneware Plc have?
Craneware Plc has 34,237,150 shares outstanding.
What happened to Craneware Plc’s price movement after its last earnings report?
Craneware Plc reported an EPS of 0.212 p in its last earnings report. Following the earnings report the stock price went down -25.782%.
Which hedge fund is a major shareholder of Craneware Plc?
Currently, no hedge funds are holding shares in GB:CRW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Craneware Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,600.00 (23.08% Upside)
£1,600.00 (23.08% Upside)
Insider Transactions
Sold Shares
Worth £277.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.21%
12-Months-Change
Fundamentals
Return on Equity
5.94%
Trailing 12-Months
Asset Growth
-2.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Craneware Plc
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improve a wide array of operational functions for healthcare organizations. Among its flagship offerings is the Chargemaster Toolkit, an automated, cloud-hosted platform for charge master administration, crucial for enabling providers to achieve optimal and legitimate revenue reimbursement. Trisus Supply facilitates the identification and resolution of data inconsistencies between disparate systems. The Physician Revenue Toolkit, a Software-as-a-Service (SaaS) solution, empowers the oversight of physician group performance indicators, billing rates, procedural codes, relative value units, and fee schedules. Complementing these are Reference Plus, another SaaS tool for comprehensive chargemaster analytics, and Pharmacy ChargeLink, engineered to bolster charge capture, pricing strategies, and cost control within pharmacy operations. Furthermore, the company offers integration software that autonomously uploads chargemaster modifications to patient billing systems, thereby ensuring billing precision. The Trisus Pricing Analyzer, a SaaS application, streamlines the pricing model development process. Extending its capabilities, Craneware delivers tools for regulatory adherence and financial oversight: InSight Medical Necessity, a SaaS solution for validating the medical necessity required by U.S. payers and for creating advance beneficiary notices; Trisus Claims Informatics, a program that automates the review of claims and coding; and InSight Audit, a browser-based audit management application for healthcare entities to handle governmental and commercial examinations. Additionally, the firm presents Trisus Healthcare Intelligence, a platform for cost analysis and resource optimization; solutions for pricing transparency; and InSight Denials, which facilitates the analysis, tracking, trending, and reporting of denial data, further supported by appeals management services. Beyond its software offerings, Craneware provides comprehensive client success management, specialized consulting, and an array of professional services. The organization also oversees its own sales, marketing efforts, and continuous product and software innovation. Founded in 1999, Craneware plc has its corporate headquarters situated in Edinburgh, United Kingdom.
CRW Stock 12 Month Forecast
Average Price Target
1,600.00 p
▲(23.08% Upside)







